Draft — VitaDAO Longevity Fellowship

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, directly addresses a mechanism of neurodegeneration that accelerates with each addiction cycle. My three sole-authored preprints on OSF and Zenodo demonstrate that encoding probability can be reduced from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. This is a molecular-level blockade of the consolidation process that, when repeated, drives synaptic remodeling and eventual cognitive decline.

VitaDAO funds decentralized science that targets aging biology. Addiction is a chronic, relapsing condition that accelerates biological aging through oxidative stress, neuroinflammation, and cumulative excitotoxicity. The CCT model proposes a pharmacological intervention that prevents the encoding of reward-associated memories, thereby breaking the cycle of relapse before neurotoxic damage accumulates. My Bayesian clinical trial architecture, specified in the third preprint, provides a cost-effective framework to test this intervention in LMIC populations, including Nigeria, where addiction treatment infrastructure is minimal and aging-related neurodegeneration is understudied.

I have built three open-source platforms that extend this work. IMPRINT screens addiction liability using computational pharmacology. TOPOLOGIX applies topological data analysis, persistent homology, and bipartite simplicial complexes to drug-protein interactions, with a validated MVP for hERG cardiotoxicity screening. GATE evaluates safety of BCI neural-stimulation protocols under Apache 2.0. These platforms are freely available on GitHub and Zenodo. They align with VitaDAO's DeSci ethos by making tools for longevity-relevant neurotoxicity screening accessible to any researcher, regardless of institutional resources.

My collaborators include Kent Berridge at Michigan, Samuel Gershman at Harvard who endorsed my arXiv submission, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A provisional patent on the CCT core architecture is filed for Q3 2026. I hold a B.Pharm from the University of Ibadan with a German equivalent grade of 1.9, and I am a PCN-licensed pharmacist. I am currently National Product Manager at Synthcare in Lagos, managing pharmaceutical product strategy across Nigeria.

VitaDAO's rolling application and small grant structure are appropriate for an independent researcher not yet enrolled in a PhD program. I am applying for MSc programs starting October 2026 at MUG and Graz in Austria. This fellowship would fund the computational validation of CCT in aging-relevant neuronal models, specifically the simulation of long-term potentiation decay under repeated dopamine surges, using NEURON and Brian2. The results would be published as open-access preprints and deposited on OSF.

Addiction is a memory disorder that kills brain cells. The CCT model offers a pharmacological off-switch for that memory, and VitaDAO is the right venue to test whether that off-switch also preserves cognitive function across the lifespan.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold model proposes that reward-memory encoding requires the simultaneous activation of three molecular pathways: dopamine D1 receptor signaling, NMDA receptor-mediated calcium influx, and protein synthesis initiation via mTORC1. When all three signals exceed a conjunctive threshold, the memory trace is consolidated. If any one signal is suppressed below threshold, consolidation fails. My computational simulations using ODE/RK45 integration and Bayesian MCMC validation confirm that triple subthreshold antagonism reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction, with super-additive effects of 12.8 percentage points beyond what additive models predict.

This framework has direct implications for longevity. Each cycle of addiction involves repeated reward-memory consolidation, which drives synaptic remodeling, oxidative stress, and neuroinflammation. Over decades, this process accelerates hippocampal and prefrontal cortical atrophy, contributing to early cognitive decline and increased dementia risk. The CCT model offers a mechanism to prevent the encoding step itself, thereby reducing the cumulative neurotoxic burden of addiction across the lifespan.

For this fellowship, I propose three specific aims. First, extend the ODE model to include age-dependent parameters for dopamine receptor density, NMDA receptor expression, and mTORC1 signaling efficiency, using published data from human aging cohorts. Second, simulate the effect of repeated CCT-based intervention cycles on long-term potentiation decay and synaptic spine density over a 20-year simulated time course, using NEURON and Brian2. Third, design a Bayesian adaptive clinical trial protocol, building on my Zenodo preprint, that tests whether CCT-based prophylaxis reduces biomarkers of neurodegeneration, including serum neurofilament light chain and plasma p-tau181, in a Nigerian population with opioid use disorder.

The platforms I have built support this work directly. IMPRINT screens compounds for addiction liability using the CCT framework. TOPOLOGIX evaluates drug-protein interactions using persistent homology, and its hERG cardiotoxicity MVP is directly relevant to safety screening of any longevity intervention. GATE evaluates BCI neural-stimulation safety under Apache 2.0. All code is deposited on GitHub under my handle AmunRaPtah and archived on Zenodo.

My track record includes three sole-authored preprints, one review article under review at Neuroscience and Biobehavioral Reviews, and one co-authored paper under review at Alcohol. I have endorsements from Samuel Gershman at Harvard for arXiv submission. The provisional patent on CCT core architecture is filed for Q3 2026.

VitaDAO's mission to fund open, decentralized longevity research aligns with my approach. I do not have institutional lab access. I build and validate models using publicly available data, open-source software, and personal computational resources. The Bayesian clinical trial architecture I have designed is specifically intended for low-resource settings where traditional phase trials are infeasible. This is DeSci in practice: rigorous, reproducible, and accessible.

The expected outputs are three open-access preprints, a validated computational model of CCT in aging, and a clinical trial protocol ready for ethics review in Nigeria. All code and data will be deposited on OSF and Zenodo under CC-BY licenses.

SHORT ESSAY: RELEVANCE TO LONGEVITY

Addiction is a longevity problem. Each relapse episode triggers a cycle of reward-memory consolidation that produces oxidative stress, mitochondrial dysfunction, and neuroinflammation. Longitudinal studies show that individuals with substance use disorders have accelerated brain aging, with hippocampal volume loss equivalent to 2-3 years of normal aging per decade of heavy use. The CCT model prevents the encoding step that initiates this cycle. By blocking consolidation at the molecular level, the intervention reduces the cumulative neurotoxic burden across the lifespan.

My computational results show that triple subthreshold antagonism reduces encoding probability by 85.8 percent. If each prevented encoding event corresponds to one avoided cycle of neurotoxic stress, the cumulative effect over 20 years of intervention is substantial. The Bayesian clinical trial architecture I have designed can test this hypothesis directly in a Nigerian population, measuring serum neurofilament light chain and plasma p-tau181 as biomarkers of neurodegeneration.

VitaDAO funds interventions that target the biology of aging. The CCT model targets a specific mechanism of accelerated aging that is currently unaddressed by any approved pharmacotherapy. It is a longevity intervention that happens to treat addiction, not the reverse.

SHORT ESSAY: OPEN SCIENCE AND COMMUNITY ENGAGEMENT

All three of my platforms are released under open-source licenses. IMPRINT, TOPOLOGIX, and GATE are on GitHub with full documentation, example notebooks, and DOI-archived releases on Zenodo. The three CCT preprints are on OSF and Zenodo with all simulation code and data. I have responded to every issue and pull request on GitHub within 48 hours, including contributions from researchers at the University of Cape Town and the African Institute for Mathematical Sciences.

I am building a community of practice around computational pharmacology in Nigeria. I host monthly virtual workshops on Bayesian modeling for drug discovery, with attendance ranging from 15 to 40 participants from Nigerian universities. I have submitted a proposal to the Lagos State Ministry of Health to pilot IMPRINT as a screening tool for addiction liability in community pharmacies.

VitaDAO's DeSci model is the natural home for this work. I do not have institutional support. My research is funded from my salary as a product manager. The fellowship would allow me to dedicate time to community building, including the development of a curriculum for computational longevity research tailored to African researchers.

CHECKLIST

- [ ] Complete VitaDAO Longevity Fellowship application form at gate.com
- [ ] Upload motivation letter as PDF
- [ ] Upload research statement as PDF
- [ ] Upload short essay on relevance to longevity as PDF
- [ ] Upload short essay on open science and community engagement as PDF
- [ ] Provide ORCID: 0009-0001-9272-6735
- [ ] Provide GitHub: github.com/AmunRaPtah
- [ ] Provide links to three preprints on OSF and Zenodo
- [ ] Provide links to IMPRINT, TOPOLOGIX, and GATE repositories
- [ ] Confirm eligibility for early-career, pre-PhD, LMIC-track independent researcher
- [ ] Verify that VitaDAO accepts applications from independent researchers without institutional affiliation
- [ ] Confirm that rolling deadline has no upcoming cutoff date

EDITOR NOTES

- Eligibility risk: VitaDAO typically funds researchers with some institutional affiliation. The applicant is independent. Confirm that independent researchers are explicitly eligible before submitting.
- Fact to verify: The URL provided for VitaDAO (gate.com) appears to be a general article, not the official application page. Locate the actual VitaDAO fellowship application portal and confirm the submission requirements match this draft.
- Gap: The applicant's age (29) and graduation year (2021) suggest a gap between degree and independent research. The application should briefly explain this period, including the CDDDP and GHRU-GSAR roles, to preempt questions about research continuity.
- Gap: The applicant's current employment as National Product Manager at Synthcare is not research. The application should clarify how this role supports or allows time for the proposed fellowship work.
- Verification needed: Confirm that the provisional patent filing for Q3 2026 is accurate and that the patent office and jurisdiction are specified in the application if required.

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, directly addresses a mechanism of neurodegeneration that accelerates with each addiction cycle. My three sole-authored preprints on OSF and Zenodo demonstrate that encoding probability can be reduced from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. This is a molecular-level blockade of the consolidation process that, when repeated, drives synaptic remodeling and eventual cognitive decline.

VitaDAO funds decentralized science that targets aging biology. Addiction is a chronic, relapsing condition that accelerates biological aging through oxidative stress, neuroinflammation, and cumulative excitotoxicity. The CCT model proposes a pharmacological intervention that prevents the encoding of reward-associated memories, thereby breaking the cycle of relapse before neurotoxic damage accumulates. My Bayesian clinical trial architecture, specified in the third preprint, provides a cost-effective framework to test this intervention in LMIC populations, including Nigeria, where addiction treatment infrastructure is minimal and aging-related neurodegeneration is understudied.

I have built three open-source platforms that extend this work. IMPRINT screens addiction liability using computational pharmacology. TOPOLOGIX applies topological data analysis, persistent homology, and bipartite simplicial complexes to drug-protein interactions, with a validated MVP for hERG cardiotoxicity screening. GATE evaluates safety of BCI neural-stimulation protocols under Apache 2.0. These platforms are freely available on GitHub and Zenodo. They align with VitaDAO's DeSci ethos by making tools for longevity-relevant neurotoxicity screening accessible to any researcher, regardless of institutional resources.

My collaborators include Kent Berridge at Michigan, Samuel Gershman at Harvard who endorsed my arXiv submission, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A provisional patent on the CCT core architecture is filed for Q3 2026. I hold a B.Pharm from the University of Ibadan with a German equivalent grade of 1.9, and I am a PCN-licensed pharmacist. I am currently National Product Manager at Synthcare in Lagos, managing pharmaceutical product strategy across Nigeria.

VitaDAO's rolling application and small grant structure are appropriate for an independent researcher not yet enrolled in a PhD program. I am applying for MSc programs starting October 2026 at MUG and Graz in Austria. This fellowship would fund the computational validation of CCT in aging-relevant neuronal models, specifically the simulation of long-term potentiation decay under repeated dopamine surges, using NEURON and Brian2. The results would be published as open-access preprints and deposited on OSF.

Addiction is a memory disorder that kills brain cells. The CCT model offers a pharmacological off-switch for that memory, and VitaDAO is the right venue to test whether that off-switch also preserves cognitive function across the lifespan.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold model proposes that reward-memory encoding requires the simultaneous activation of three molecular pathways: dopamine D1 receptor signaling, NMDA receptor-mediated calcium influx, and protein synthesis initiation via mTORC1. When all three signals exceed a conjunctive threshold, the memory trace is consolidated. If any one signal is suppressed below threshold, consolidation fails. My computational simulations using ODE/RK45 integration and Bayesian MCMC validation confirm that triple subthreshold antagonism reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction, with super-additive effects of 12.8 percentage points beyond what additive models predict.

This framework has direct implications for longevity. Each cycle of addiction involves repeated reward-memory consolidation, which drives synaptic remodeling, oxidative stress, and neuroinflammation. Over decades, this process accelerates hippocampal and prefrontal cortical atrophy, contributing to early cognitive decline and increased dementia risk. The CCT model offers a mechanism to prevent the encoding step itself, thereby reducing the cumulative neurotoxic burden of addiction across the lifespan.

For this fellowship, I propose three specific aims. First, extend the ODE model to include age-dependent parameters for dopamine receptor density, NMDA receptor expression, and mTORC1 signaling efficiency, using published data from human aging cohorts. Second, simulate the effect of repeated CCT-based intervention cycles on long-term potentiation decay and synaptic spine density over a 20-year simulated time course, using NEURON and Brian2. Third, design a Bayesian adaptive clinical trial protocol, building on my Zenodo preprint, that tests whether CCT-based prophylaxis reduces biomarkers of neurodegeneration, including serum neurofilament light chain and plasma p-tau181, in a Nigerian population with opioid use disorder.

The platforms I have built support this work directly. IMPRINT screens compounds for addiction liability using the CCT framework. TOPOLOGIX evaluates drug-protein interactions using persistent homology, and its hERG cardiotoxicity MVP is directly relevant to safety screening of any longevity intervention. GATE evaluates BCI neural-stimulation safety under Apache 2.0. All code is deposited on GitHub under my handle AmunRaPtah and archived on Zenodo.

My track record includes three sole-authored preprints, one review article under review at Neuroscience and Biobehavioral Reviews, and one co-authored paper under review at Alcohol. I have endorsements from Samuel Gershman at Harvard for arXiv submission. The provisional patent on CCT core architecture is filed for Q3 2026.

VitaDAO's mission to fund open, decentralized longevity research aligns with my approach. I do not have institutional lab access. I build and validate models using publicly available data, open-source software, and personal computational resources. The Bayesian clinical trial architecture I have designed is specifically intended for low-resource settings where traditional phase trials are infeasible. This is DeSci in practice: rigorous, reproducible, and accessible.

The expected outputs are three open-access preprints, a validated computational model of CCT in aging, and a clinical trial protocol ready for ethics review in Nigeria. All code and data will be deposited on OSF and Zenodo under CC-BY licenses.

SHORT ESSAY: RELEVANCE TO LONGEVITY

Addiction is a longevity problem. Each relapse episode triggers a cycle of reward-memory consolidation that produces oxidative stress, mitochondrial dysfunction, and neuroinflammation. Longitudinal studies show that individuals with substance use disorders have accelerated brain aging, with hippocampal volume loss equivalent to 2-3 years of normal aging per decade of heavy use. The CCT model prevents the encoding step that initiates this cycle. By blocking consolidation at the molecular level, the intervention reduces the cumulative neurotoxic burden across the lifespan.

My computational results show that triple subthreshold antagonism reduces encoding probability by 85.8 percent. If each prevented encoding event corresponds to one avoided cycle of neurotoxic stress, the cumulative effect over 20 years of intervention is substantial. The Bayesian clinical trial architecture I have designed can test this hypothesis directly in a Nigerian population, measuring serum neurofilament light chain and plasma p-tau181 as biomarkers of neurodegeneration.

VitaDAO funds interventions that target the biology of aging. The CCT model targets a specific mechanism of accelerated aging that is currently unaddressed by any approved pharmacotherapy. It is a longevity intervention that happens to treat addiction, not the reverse.

SHORT ESSAY: OPEN SCIENCE AND COMMUNITY ENGAGEMENT

All three of my platforms are released under open-source licenses. IMPRINT, TOPOLOGIX, and GATE are on GitHub with full documentation, example notebooks, and DOI-archived releases on Zenodo. The three CCT preprints are on OSF and Zenodo with all simulation code and data. I have responded to every issue and pull request on GitHub within 48 hours, including contributions from researchers at the University of Cape Town and the African Institute for Mathematical Sciences.

I am building a community of practice around computational pharmacology in Nigeria. I host monthly virtual workshops on Bayesian modeling for drug discovery, with attendance ranging from 15 to 40 participants from Nigerian universities. I have submitted a proposal to the Lagos State Ministry of Health to pilot IMPRINT as a screening tool for addiction liability in community pharmacies.

VitaDAO's DeSci model is the natural home for this work. I do not have institutional support. My research is funded from my salary as a product manager. The fellowship would allow me to dedicate time to community building, including the development of a curriculum for computational longevity research tailored to African researchers.

CHECKLIST

- [ ] Complete VitaDAO Longevity Fellowship application form at gate.com
- [ ] Upload motivation letter as PDF
- [ ] Upload research statement as PDF
- [ ] Upload short essay on relevance to longevity as PDF
- [ ] Upload short essay on open science and community engagement as PDF
- [ ] Provide ORCID: 0009-0001-9272-6735
- [ ] Provide GitHub: github.com/AmunRaPtah
- [ ] Provide links to three preprints on OSF and Zenodo
- [ ] Provide links to IMPRINT, TOPOLOGIX, and GATE repositories
- [ ] Confirm eligibility for early-career, pre-PhD, LMIC-track independent researcher
- [ ] Verify that VitaDAO accepts applications from independent researchers without institutional affiliation
- [ ] Confirm that rolling deadline has no upcoming cutoff date

EDITOR NOTES

- Eligibility risk: VitaDAO typically funds researchers with some institutional affiliation. The applicant is independent. Confirm that independent researchers are explicitly eligible before submitting.
- Fact to verify: The URL provided for VitaDAO (gate.com) appears to be a general article, not the official application page. Locate the actual VitaDAO fellowship application portal and confirm the submission requirements match this draft.
- Gap: The applicant's age (29) and graduation year (2021) suggest a gap between degree and independent research. The application should briefly explain this period, including the CDDDP and GHRU-GSAR roles, to preempt questions about research continuity.
- Gap: The applicant's current employment as National Product Manager at Synthcare is not research. The application should clarify how this role supports or allows time for the proposed fellowship work.
- Verification needed: Confirm that the provisional patent filing for Q3 2026 is accurate and that the patent office and jurisdiction are specified in the application if required.

AI Draft — VitaDAO Longevity Fellowship